Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia

Top Cited Papers
Open Access
Abstract
Compared with less differentiated acute myeloid leukemia (AML), monocytic AML is more resistant to venetoclax-based therapy, a phenomenon that may be attributable to dedifferentiation of preexisting monocytic subclones.
Funding Information
  • NIH (R01CA200707)
  • University of Colorado
  • Department of Medicine Outstanding Early Career Scholar Program
  • Leukaemia and Lymphoma Research
  • Leukaemia and Lymphoma Research
  • E.P. Evans Foundation Biff Ruttenberg Foundation
  • NIH (GM008497, 25A5072)
  • Boettcher Foundation
  • Leukemia and Lymphoma Society
  • American Cancer Society (25A5072)
  • University of Colorado Cancer Center (P30CA046934)